USP comments to FDA on Guidance For Industry on Microbiological Quality Considerations in Nonsterile Drug Manufacturing (2021)

USP comments to FDA on Docket No. FDA-2021-D-0432 for “Microbiological Quality Considerations in Non-Sterile Drug Manufacturing”. Comments were submitted in 2021.

USP-comments-to-FDA-on-GFI-Micro-Quality-in-Nonsterile-Drugs.pdf (181.88 KB)

Public Policy